CD4 News and Research

RSS

How durable is the immune response generated from the BNT162b2 vaccine?

In a recent study, researchers analyzed antibody responses to the homologous Wu strain and several other SARS-CoV-2 variants after BNT162b2 vaccination.

4 Oct 2021

Persistent leukocyte changes three months after mild SARS-CoV-2 infection

A recent study discusses the rate of changes in peripheral blood white cells in individuals who have recovered from SARS-CoV-2 infection.

3 Oct 2021

Research provides the basis for an additional novel immunotherapy for multiple myeloma patients

Oncotarget published "Multipeptide stimulated PBMCs generate TEM/TCM for adoptive cell therapy in multiple myeloma" which reported that Multiple Myeloma patients suffer disease relapse due to the development of therapeutic resistance. Increasing evidence suggests that immunotherapeutic strategies can provide durable responses.

29 Sep 2021

Chronic COVID-19 and divergent variants of SARS-CoV-2

A new study discusses the isolation of two variants of concern (VOCs) from an immunocompromised COVID-19 patient.

27 Sep 2021

Review of COVID-19 clinical and viral characteristics, pathogenesis, and genetics

A new review article investigates the clinical and viral characteristics, pathogenesis, as well as human genetic basis associated with COVID-19.

27 Sep 2021

Design of peptide vaccine for SARS-CoV-2

In a recent study, researchers from the US identified two immunogenic non-structural proteins - PLpro and RdRp - from immunodominant gene regions ORF1ab, ORF3a and ORF9b as potential targets for a vaccine against SARS-CoV-2.

27 Sep 2021

Varying immune responses after single dose of Pfizer and AstraZeneca COVID-19 vaccines

A new preprint describes the significant variation in the early immune response elicited by two of the earliest vaccines to gain emergency authorization against COVID-19.

23 Sep 2021

Differences in blood gene expression among patients with varying COVID-19 severity

A new study published on the medRxiv* pre-print server and currently undergoing peer-review aims to answer this question through whole blood transcriptomics of individuals with varying degrees of COVID-19 severity. Transcriptomics, done by RNA sequencing, gives insights into the genes expressed in a cell at a given time point. It gives an analysis of all RNA molecules within a cell, in this case, whole blood.

23 Sep 2021

The impact of multiple sclerosis therapy on COVID-19 vaccine efficacy

In a paper, the vaccine-induced cellular and immune response of MS patients receiving a range of therapies are assessed.

23 Sep 2021

Implications of dosing sparing and booster shots in the context of prior SARS-CoV-2 infection

The current study suggests that deferring the second vaccination of individuals with prior infection may be a cost-effective strategy.

21 Sep 2021

Scientists identify potential therapeutic targets to alleviate severe COVID-19 in aged patients

The scientists assessed epidemiological data from March to December 2020 from the CDC to investigate the prevalence of COVID-19 disease among different age groups.

21 Sep 2021

T cell immunity induced after mild COVID could contribute to protection against re-infection

An interesting new study finds that in both adults and children, a mild infection with the SARS-CoV-2 elicits an antigen-specific memory T-cell response.

20 Sep 2021

Humoral and cellular response to COVID-19 vaccines in patients with IBD

A new study published in the preprint server medRxiv* aimed to evaluate the humoral and cellular response to COVID-19 vaccine in patients with IBD undergoing biologic or immunomodulatory therapy.

17 Sep 2021

Multiple sclerosis patients elicit robust T-cell responses to mRNA COVID-19 vaccines

New research shows that Multiple Sclerosis (MS) patients undergoing anti-CD20 (aCD20) treatment – which depletes the B cells that contribute to the MS attacks – are able to mount robust T-cell responses to the mRNA COVID-19 vaccines, despite having a muted antibody response to the vaccines.

17 Sep 2021

Three doses of inactivated BBIBP-CorV SARS-CoV-2 vaccine induce robust B and T cell responses

To investigate the immune memory sustainability of SARS-CoV-2-specific B cells and T cells, stimulated by the inactivated vaccine, and the potential need for a third booster dose in healthcare workers (HCWs), a non-randomized trial was undertaken by researchers at Sun Yat-sen University in Guangzhou, China. the research is posted online on the medRxiv* preprint server.

17 Sep 2021

Flavonoids can potentially help prevent COVID-19-induced diarrhea, study finds

A recent study published in Tropical Biomedicine determines whether flavonoids can help prevent diarrhea caused by SARS-CoV-2 infection.

15 Sep 2021

Deep profiling of SARS-CoV-2 immune response amongst the mildly symptomatic

In a research paper recently uploaded to the medRxiv* preprint server by Capelle et al. (September 2nd, 2021), the immune response of mild and hospitalized COVID-19 patients is compared, finding that early T-cell response is a vital indicator of SARS-CoV-2 disease severity.

15 Sep 2021

CD4 News and Research

How durable is the immune response generated from the BNT162b2 vaccine?

Persistent leukocyte changes three months after mild SARS-CoV-2 infection

Research provides the basis for an additional novel immunotherapy for multiple myeloma patients

Chronic COVID-19 and divergent variants of SARS-CoV-2

Review of COVID-19 clinical and viral characteristics, pathogenesis, and genetics

Design of peptide vaccine for SARS-CoV-2

Varying immune responses after single dose of Pfizer and AstraZeneca COVID-19 vaccines

Differences in blood gene expression among patients with varying COVID-19 severity

The impact of multiple sclerosis therapy on COVID-19 vaccine efficacy

Implications of dosing sparing and booster shots in the context of prior SARS-CoV-2 infection

Scientists identify potential therapeutic targets to alleviate severe COVID-19 in aged patients

T cell immunity induced after mild COVID could contribute to protection against re-infection

Humoral and cellular response to COVID-19 vaccines in patients with IBD

Multiple sclerosis patients elicit robust T-cell responses to mRNA COVID-19 vaccines

Three doses of inactivated BBIBP-CorV SARS-CoV-2 vaccine induce robust B and T cell responses

Flavonoids can potentially help prevent COVID-19-induced diarrhea, study finds

Deep profiling of SARS-CoV-2 immune response amongst the mildly symptomatic

Flu shots and COVID-19 immunity

MS patients receiving aCD20 treatment mount robust T-cell responses to COVID-19 vaccines

Low dose of Moderna COVID-19 vaccine generates durable immune response

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News